(secondQuint)A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults.

 This study evaluates the safety and immunogenicity of the Chiron vaccine HIV p24/MF59.

 In Part A, 15 volunteers are randomly assigned to receive either HIV p24/MF59 or a placebo at 0, 1, and 6 months.

 10 volunteers receive the vaccine and 5 volunteers receive the placebo.

 If no serious adverse events are observed within 1 week after the first injection in these first 15 patients, Part B is initiated.

 In Part B, 25 volunteers are randomly assigned to receive HIV p24/MF59 or a placebo at 0, 1, and 6 months.

 20 volunteers receive the vaccine and 5 volunteers receive the placebo.

.

 A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults@highlight

To evaluate the safety and tolerability of the Chiron vaccine human immunodeficiency virus (HIV) p24(25 or 50 micrograms)/MF59 in healthy HIV-1 seronegative adults.

 To evaluate the immunogenicity of the HIV p24(50 micrograms)/MF59 vaccine.

